Potential application of biliverdin reductase and its fragments to modulate insulin/IGF-1/MAPK/PI3-K signaling pathways in therapeutic settings

Current Drug Targets

Volumn 11, Issue 12, 2010, Pages 1586-1594

  Maines, Mahin D ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Antioxidants; Bile pigments; Biliverdin reductase; Insulin IGF 1 signaling; MAPK PI3 K signal transduction pathways; Protein kinases

Indexed keywords

BILE PIGMENT; BILIVERDIN REDUCTASE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; OXIDOREDUCTASE; PHOSPHATIDYLINOSITOL 3 KINASE; SCAFFOLD PROTEIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; BILIRUBIN; HEME OXYGENASE; INSULIN RECEPTOR; PEPTIDE FRAGMENT; SOMATOMEDIN C RECEPTOR;

CYCLIC AMP RESPONSIVE ELEMENT; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; NONHUMAN; REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BILE PIGMENTS; BILIRUBIN; DRUG DESIGN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEME OXYGENASE (DECYCLIZING); HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MAP KINASE SIGNALING SYSTEM; OXIDATIVE STRESS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PEPTIDE FRAGMENTS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 79952277022     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111009011586     Document Type: Review

References (76)

1. Schluchter WM, Glazer AN. Characterization of cyanobacterial biliverdin reductase. Conversion of biliverdin to bilirubin is important for normal phycobiliprotein biosynthesis. J Biol Chem 1997; 272: 13562-9.
2. Kohchi T, Mukougawa K, Frankenberg N, Masuda M, Yokota A, Lagarias JC. The Arabidopsis HY2 gene encodes phytochromobilin synthase, a ferredoxin-dependent biliverdin reductase. Plant Cell 2001; 13: 425-36.
3. Kapitulnik J, Maines MD. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol Sci 2009; 30: 129-37.
4. Pereira PJ, Macedo-Ribeiro S, Parraga A, et al. Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme. Nat Struct Biol 2001; 8: 215-20.
5. Kutty RK, Maines MD. Purification and characterization of biliverdin reductase from rat liver. J Biol Chem 1981; 256: 3956-62.
6. Whitby FG, Phillips JD, Hill CP, McCoubrey W, Maines MD. Crystal structure of a biliverdin IX alpha reductase enzymecofactor complex. J Mol Biol 2002; 319: 1199-210.
7. Florczyk UM, Jozkowicz A, Dulak J. Biliverdin reductase: new features of an old enzyme and its potential therapeutic significance. Pharmacol Rep 2008; 60: 38-48.
8. Niittynen M, Tuomisto JT, Auriola S, et al. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced accumulation of biliverdin and hepatic peliosis in rats. Toxicol Sci 2003; 71: 112-23.
9. Gafvels M, Holmstrom P, Somell A, et al. A novel mutation in the biliverdin reductase-A gene combined with liver cirrhosis results in hyperbiliverdinaemia (green jaundice). Liver Int 2009; 29: 1116-24.
10. Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008; 198: 1-11.
11. Nakao A, Otterbein LE, Overhaus M, et al. Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology 2004; 127: 595-606.
12. Ollinger R, Wang H, Yamashita K, et al. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid Redox Signal 2007; 9: 2175-85.
13. Liu Y, Liu J, Tetzlaff W, Paty DW, Cynader MS. Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. Free Radic Biol Med 2006; 40: 960-7.
14. Wang WW, Smith DL, Zucker SD. Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology 2004; 40: 424-33.
15. Sarady-Andrews JK, Liu F, Gallo D, et al. Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol 2005; 289: L1131-7.
16. Ohrui T, Yasuda H, Yamaya M, Matsui T, Sasaki H. Transient relief of asthma symptoms during jaundice: a possible beneficial role of bilirubin. Tohoku J Exp Med 2003; 199: 193-6.
17. Kitamura Y, Ishida Y, Takata K, et al. Hyperbilirubinemia protects against focal ischemia in rats. J Neurosci Res 2003; 71(4): 544-50.
18. Bernhard W, Gautier A, Rouiller C. The concept of microsomes and the problem of cytoplasmic basophilia; critical and experimental study. Arch Anat Pathol (Paris) 1954; 43: 236-75.
19. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-6.
20. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 269: 16712-9.
21. Maghzal GJ, Leck MC, Collinson E, Li C, Stocker R. Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase. J Biol Chem 2009; 284: 29251-9.
22. Papiez MA, Dybala M, Sowa-Kucma M, et al. Evaluation of oxidative status and depression-like responses in Brown Norway rats with acute myeloid leukemia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 596-604.
23. Hunt SC, Kronenberg F, Eckfeldt JH, Hopkins PN, Myers RH, Heiss G. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis 2001; 154: 747-54.
24. Temme EH, Zhang J, Schouten EG, Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 2001; 12: 887-94.
25. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 2000; 46: 1723-7.
26. Vitek L, Kraslova I, Muchova L, Novotny L, Yamaguchi T. Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome. J Gastroenterol Hepatol 2007; 22: 841-5.
27. Maines MD. Heme oxygenase: clinical applications and functions. Boca Raton, FL: CRC Press Inc 1992.
28. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517-54.
29. Maines MD, Trakshel GM. Purification and characterization of human biliverdin reductase. Arch Biochem Biophys 1993; 300: 320-6.
30. Hayes JM, Mantle TJ. The effect of pH on the initial rate kinetics of the dimeric biliverdin-IXalpha reductase from the cyanobacterium Synechocystis PCC6803. FEBS J 2009; 276: 4414-25.
31. Perozich J, Kuo I, Wang BC, Boesch JS, Lindahl R, Hempel J. Shifting the NAD/NADP preference in class 3 aldehyde dehydrogenase. Eur J Biochem 2000; 267(20): 6197-203.
32. Smith LJ, Browne S, Mulholland AJ, Mantle TJ. Computational and experimental studies on the catalytic mechanism of biliverdin-IXbeta reductase. Biochem J 2008; 411: 475-84.
33. Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA 2009; 106: 5171-6.
34. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002; 99: 16093-8.
35. Perez MJ, Castano B, Jimenez S, Serrano MA, Gonzalez-Buitrago JM, Marin JJ. Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal unit in cholestasis during pregnancy. Toxicol Appl Pharmacol 2008; 232: 327-36.
36. Franklin E, Browne S, Hayes J, et al. Activation of biliverdin-IXalpha reductase by inorganic phosphate and related anions. Biochem J 2007; 405: 61-7.
37. Gibbs PE, Miralem T, Maines MD. Characterization of the human biliverdin reductase gene structure and regulatory elements: promoter activity is enhanced by hypoxia and suppressed by TNF-{alpha}-activated NF-{kappa}B. FASEB J Apr 21 [Epub ahead of print] PMID: 20410444.
38. Maines MD, Ewing JF, Huang TJ, Panahian N. Nuclear localization of biliverdin reductase in the rat kidney: response to nephrotoxins that induce heme oxygenase-1. J Pharmacol Exp Ther 2001; 296: 1091-7.
39. Ewing JF, Maines MD. Immunohistochemical localization of biliverdin reductase in rat brain: age related expression of protein and transcript. Brain Res 1995; 672: 29-41.
40. Niittynen M, Tuomisto JT, Pohjanvirta R. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on heme oxygenase-1, biliverdin IX alpha reductase and delta-aminolevulinic acid synthetase 1 in rats with wild-type or variant AH receptor. Toxicology 2008; 250: 132-42.
41. Wegiel B, Baty CJ, Gallo D, et al. Cell surface biliverdin reductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt. J Biol Chem 2009; 284: 21369-78.
42. Maines MD, Mayer RD, Erturk E, Huang TJ, Disantagnese A. The oxidoreductase, biliverdin reductase, is induced in human renal carcinoma--pH and cofactor-specific increase in activity. J Urol 1999; 162: 1467-72.
43. McCoubrey WK, Jr., Cooklis MA, Maines MD. The structure, organization and differential expression of the rat gene encoding biliverdin reductase. Gene 1995; 160: 235-40.
44. Puga A, Barnes SJ, Chang C, et al. Activation of transcription factors activator protein-1 and nuclear factor-kappaB by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Pharmacol 2000; 59: 997-1005.
45. Salim M, Brown-Kipphut BA, Maines MD. Human biliverdin reductase is autophosphorylated, and phosphorylation is required for bilirubin formation. J Biol Chem 2001; 276: 10929-34.
46. Cornejo J, Willows RD, Beale SI. Phytobilin biosynthesis: cloning and expression of a gene encoding soluble ferredoxin-dependent heme oxygenase from Synechocystis sp. PCC 6803. Plant J 1998; 15: 99-107.
47. Terry MJ, Lagarias JC. Holophytochrome assembly. Coupled assay for phytochromobilin synthase in organello. J Biol Chem 1991; 266: 22215-21.
48. Gambetta GA, Lagarias JC. Genetic engineering of phytochrome biosynthesis in bacteria. Proc Natl Acad Sci USA 2001; 98: 10566-71.
49. Maines MD. Biliverdin reductase: PKC interaction at the cross-talk of MAPK and PI3K signaling pathways. Antioxid Redox Signal 2007; 9: 2187-95.
50. Falchuk KH, Contin JM, Dziedzic TS, et al. A role for biliverdin IXalpha in dorsal axis development of Xenopus laevis embryos. Proc Natl Acad Sci USA 2002; 99: 251-6.
51. Lombard MN, Houssais JF, Decloitre F, Dutrillaux B. Liver cells can spontaneously resume proliferation in long-term quiescent primary cultures. Cell Prolif 1994; 27: 177-89.
52. Wen WN. Methemoglobin contributes to the growth of human tumor cells. Life Sci 2002; 70: 907-16.
53. Phelan D, Winter GM, Rogers WJ, Lam JC, Denison MS. Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch Biochem Biophys 1998; 357: 155-63.
54. Sinal CJ, Bend JR. Aryl hydrocarbon receptor-dependent induction of cyp1a1 by bilirubin in mouse hepatoma hepa 1c1c7 cells. Mol Pharmacol 1997; 52: 590-9.
55. Bulmer AC, Ried K, Coombes JS, Blanchfield JT, Toth I, Wagner KH. The anti-mutagenic and antioxidant effects of bile pigments in the Ames Salmonella test. Mutat Res 2007; 629: 122-32.
56. Gibbs PE, Maines MD. Biliverdin inhibits activation of NFkappaB: reversal of inhibition by human biliverdin reductase. Int J Cancer 2007; 121: 2567-74.
57. Kapitulnik J, Gonzalez FJ. Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat. Mol Pharmacol 1993; 43: 722-5.
58. Kapitulnik J. Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol 2004; 66: 773-9.
59. Lerner-Marmarosh N, Shen J, Torno MD, Kravets A, Hu Z, Maines MD. Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. Proc Natl Acad Sci USA 2005; 102: 7109-14.
60. Miralem T, Hu Z, Torno MD, Lelli KM, Maines MD. Small interference RNA-mediated gene silencing of human biliverdin reductase, but not that of heme oxygenase-1, attenuates arsenitemediated induction of the oxygenase and increases apoptosis in 293A kidney cells. J Biol Chem 2005; 280: 17084-92.
61. Lerner-Marmarosh N, Miralem T, Gibbs PE, Maines MD. Regulation of TNF-alpha-activated PKC-zeta signaling by the human biliverdin reductase: identification of activating and inhibitory domains of the reductase. FASEB J 2007; 21: 3949-62.
62. Miralem T, Gibbs PE, Revert F, Saus J, Maines MD. Human biliverdin reductase suppresses goodpasture antigen binding protein (GPBP) kinase activity: the reductase regulates TNF-{alpha}-NF-{kappa}B-dependent GPBP expression. J Biol Chem 2010; 285: 12551-8.
63. Tudor C, Lerner-Marmarosh N, Engelborghs Y, Gibbs PE, Maines MD. Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. Biochem J 2008; 413: 405-16.
64. Maines MD, Miralem T, Lerner-Marmarosh N, Shen J, Gibbs PE. Human biliverdin reductase, a previously unknown activator of protein kinase C betaII. J Biol Chem 2007; 282: 8110-22.
65. Lerner-Marmarosh N, Miralem T, Gibbs PE, Maines MD. Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. Proc Natl Acad Sci USA 2008; 105: 6870-5.
66. Kirkby K, Baylis C, Agarwal A, Croker B, Archer L, Adin C. Intravenous bilirubin provides incomplete protection against renal ischemia-reperfusion injury in vivo. Am J Physiol Renal Physiol 2007; 292: F888-94.
67. Suzuki H, Tashiro S, Hira S, et al. Heme regulates gene expression by triggering Crm1-dependent nuclear export of Bach1. EMBO J 2004; 23: 2544-53.
68. Ahmad Z, Salim M, Maines MD. Human biliverdin reductase is a leucine zipper-like DNA-binding protein and functions in transcriptional activation of heme oxygenase-1 by oxidative stress. J Biol Chem 2002; 277: 9226-32.
69. Kravets A, Hu Z, Miralem T, Torno MD, Maines MD. Biliverdin reductase, a novel regulator for induction of activating transcription factor-2 and heme oxygenase-1. J Biol Chem 2004; 279: 19916-23.
70. Pachori AS, Smith A, McDonald P, Zhang L, Dzau VJ, Melo LG. Heme-oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway. J Mol Cell Cardiol 2007; 43: 580-92.
71. Zeng R, Yao Y, Han M, et al. Biliverdin reductase mediates hypoxia-induced EMT via PI3-kinase and Akt. J Am Soc Nephrol 2008; 19: 380-7.
72. Melle C, Ernst G, Scheibner O, et al. Identification of specific protein markers in microdissected hepatocellular carcinoma. J Proteome Res 2007; 6: 306-15.
73. Kaidanovich-Beilin O, Eldar-Finkelman H. Peptides targeting protein kinases: strategies and implications. Physiology (Bethesda) 2006; 21: 411-8.
74. Newton AC. Regulation of protein kinase C. Curr Opin Cell Biol 1997; 9: 161-7.
75. Fields AP, Gustafson WC. Protein kinase C in disease: cancer. Methods Mol Biol 2003; 233: 519-37.
76. Maines MD. New insights into biliverdin reductase functions: linking heme metabolism to cell signaling. Physiology (Bethesda) 2005; 20: 382-9.